• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

溶栓治疗后神经功能恶化的缺血性脑卒中患者发生症状性颅内出血的预测因素。

Predictors of symptomatic intracranial haemorrhage in patients with an ischaemic stroke with neurological deterioration after intravenous thrombolysis.

机构信息

Department of Neurology, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.

Department of Diagnostic Imaging, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.

出版信息

J Neurol Neurosurg Psychiatry. 2018 Aug;89(8):866-869. doi: 10.1136/jnnp-2017-317341. Epub 2018 Feb 27.

DOI:10.1136/jnnp-2017-317341
PMID:29487169
Abstract

OBJECTIVES

Early neurological deterioration prompting urgent brain imaging occurs in nearly 15% of patients with ischaemic stroke receiving intravenous tissue plasminogen activator (tPA). We aim to determine risk factors associated with symptomatic intracranial haemorrhage (sICH) in patients with ischaemic stroke undergoing emergent brain imaging for early neurological deterioration after receiving tPA.

METHODS

We abstracted data from our prospective stroke database and included all patients receiving tPA for ischaemic stroke between 1 March 2015 and 1 March 2017. We then identified patients with neurological deterioration who underwent urgent brain imaging prior to their per-protocol surveillance imaging and divided patients into two groups: those with and without sICH. We compared baseline demographics, clinical variables, in-hospital treatments and functional outcomes at 90 days between the two groups.

RESULTS

We identified 511 patients who received tPA, of whom 108 (21.1%) had an emergent brain CT. Of these patients, 17.5% (19/108) had sICH; 21.3% (23/108) of emergent scans occurred while tPA was infusing, though only 4.3% of these scans (1/23) revealed sICH. On multivariable analyses, the only predictor of sICH was a change in level of consciousness (OR 6.62, 95% CI 1.64 to 26.70, P=0.008).

CONCLUSION

Change in level of consciousness is associated with sICH among patients undergoing emergent brain imaging after receiving tPA. In this group of patients, preparation of tPA reversal agents while awaiting brain imaging may reduce reversal times. Future studies are needed to study the cost-effectiveness of this approach.

摘要

目的

接受静脉组织型纤溶酶原激活剂(tPA)治疗的缺血性脑卒中患者中,近 15%会出现促使紧急脑部成像的早期神经功能恶化。我们旨在确定在接受 tPA 治疗后因早期神经功能恶化而紧急进行脑部成像的缺血性脑卒中患者中,与症状性颅内出血(sICH)相关的危险因素。

方法

我们从前瞻性脑卒中数据库中提取数据,纳入 2015 年 3 月 1 日至 2017 年 3 月 1 日期间接受 tPA 治疗的所有缺血性脑卒中患者。然后,我们确定了在按方案进行监测成像之前出现神经功能恶化并进行紧急脑部成像的患者,并将患者分为两组:有 sICH 组和无 sICH 组。我们比较了两组患者的基线人口统计学资料、临床变量、住院治疗和 90 天的功能结局。

结果

我们共纳入了 511 例接受 tPA 治疗的患者,其中 108 例(21.1%)进行了紧急脑部 CT 检查。这些患者中,17.5%(19/108)出现 sICH;108 例患者中 21.3%(23/108)在 tPA 输注时进行了紧急扫描,但只有 4.3%(1/23)的扫描显示 sICH。多变量分析显示,sICH 的唯一预测因素是意识水平的变化(OR 6.62,95%CI 1.64 至 26.70,P=0.008)。

结论

在接受 tPA 治疗后进行紧急脑部成像的患者中,意识水平的变化与 sICH 相关。在这群患者中,在等待脑部成像的同时准备 tPA 逆转剂可能会缩短逆转时间。需要进一步研究这种方法的成本效益。

相似文献

1
Predictors of symptomatic intracranial haemorrhage in patients with an ischaemic stroke with neurological deterioration after intravenous thrombolysis.溶栓治疗后神经功能恶化的缺血性脑卒中患者发生症状性颅内出血的预测因素。
J Neurol Neurosurg Psychiatry. 2018 Aug;89(8):866-869. doi: 10.1136/jnnp-2017-317341. Epub 2018 Feb 27.
2
Influence of antiplatelet pre-treatment on the risk of intracranial haemorrhage in acute ischaemic stroke after intravenous thrombolysis.抗血小板预处理对急性缺血性脑卒中静脉溶栓后颅内出血风险的影响。
Eur J Neurol. 2010 Feb;17(2):301-6. doi: 10.1111/j.1468-1331.2009.02843.x. Epub 2009 Nov 12.
3
Race/Ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy.接受溶栓治疗的缺血性脑卒中患者发生出血性并发症的风险的种族/民族差异。
Stroke. 2014 Aug;45(8):2263-9. doi: 10.1161/STROKEAHA.114.005019. Epub 2014 Jun 24.
4
Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.低剂量组织型纤溶酶原激活剂治疗急性缺血性卒中:一项系统评价和Meta分析
J Stroke Cerebrovasc Dis. 2018 Feb;27(2):381-390. doi: 10.1016/j.jstrokecerebrovasdis.2017.09.014. Epub 2017 Oct 27.
5
Predictors of in-hospital mortality and the risk of symptomatic intracerebral hemorrhage after thrombolytic therapy with recombinant tissue plasminogen activator in acute ischemic stroke.重组组织型纤溶酶原激活剂溶栓治疗急性缺血性脑卒中后院内死亡率及症状性颅内出血的风险预测因素。
J Stroke Cerebrovasc Dis. 2014 Jan;23(1):7-11. doi: 10.1016/j.jstrokecerebrovasdis.2012.04.004. Epub 2012 May 11.
6
Prevalence of early neurological deterioration after I.V - thrombolysis in acute ischaemic stroke patients - A hospital-based cohort study.急性缺血性中风患者静脉溶栓后早期神经功能恶化的患病率——一项基于医院的队列研究。
Clin Neurol Neurosurg. 2018 Aug;171:58-62. doi: 10.1016/j.clineuro.2018.05.003. Epub 2018 May 5.
7
Renal Dysfunction Associated with Symptomatic Intracranial Hemorrhage after Intravenous Thrombolysis.静脉溶栓后与症状性颅内出血相关的肾功能障碍。
J Stroke Cerebrovasc Dis. 2019 Nov;28(11):104363. doi: 10.1016/j.jstrokecerebrovasdis.2019.104363. Epub 2019 Sep 6.
8
Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children.儿童急性脑卒中静脉注射 tPA(组织型纤溶酶原激活物)后颅内出血的风险较低。
Stroke. 2020 Feb;51(2):542-548. doi: 10.1161/STROKEAHA.119.027225. Epub 2019 Dec 17.
9
Clotting factors to treat thrombolysis-related symptomatic intracranial hemorrhage in acute ischemic stroke.用于治疗急性缺血性卒中溶栓相关症状性颅内出血的凝血因子。
J Stroke Cerebrovasc Dis. 2014 Mar;23(3):e207-14. doi: 10.1016/j.jstrokecerebrovasdis.2013.10.009. Epub 2013 Dec 8.
10
The Etiologies of Early Neurological Deterioration after Thrombolysis and Risk Factors of Ischemia Progression.溶栓后早期神经功能恶化的病因及缺血进展的危险因素。
J Stroke Cerebrovasc Dis. 2016 Feb;25(2):383-8. doi: 10.1016/j.jstrokecerebrovasdis.2015.10.010. Epub 2015 Nov 17.

引用本文的文献

1
Should we switch to tenecteplase for all ischemic strokes? Evidence and logistics.对于所有缺血性中风患者,我们都应该改用替奈普酶吗?证据与后勤考量。
Int J Stroke. 2025 Mar;20(3):261-267. doi: 10.1177/17474930241307098. Epub 2025 Jan 6.
2
Neuroprotective Effect and Possible Mechanisms of Ginsenoside-Rd for Cerebral Ischemia/Reperfusion Damage in Experimental Animal: A Meta-Analysis and Systematic Review.人参皂苷-Rd 对实验性动物脑缺血/再灌注损伤的神经保护作用及可能机制:Meta 分析和系统评价。
Oxid Med Cell Longev. 2022 Sep 1;2022:7650438. doi: 10.1155/2022/7650438. eCollection 2022.
3
Subsequent Subarachnoid Hemorrhage from Clinically Unrelated Vertebral Artery Dissection after Thrombolytic Therapy.
溶栓治疗后因临床无关的椎动脉夹层导致的迟发性蛛网膜下腔出血
Neurointervention. 2022 Mar;17(1):54-57. doi: 10.5469/neuroint.2021.00458. Epub 2022 Jan 17.
4
Early Neurological Deterioration Despite Recanalization in Basilar Artery Occlusion Treated by Endovascular Therapy.尽管采用血管内治疗使基底动脉闭塞再通,但仍出现早期神经功能恶化。
Front Neurol. 2020 Nov 19;11:592003. doi: 10.3389/fneur.2020.592003. eCollection 2020.
5
Diagnosis and management of acute ischaemic stroke.急性缺血性脑卒中的诊断与管理
Pract Neurol. 2020 Aug;20(4):304-316. doi: 10.1136/practneurol-2020-002557. Epub 2020 Jun 7.
6
Differences between predictive factors for early neurological deterioration due to hemorrhagic and ischemic insults following intravenous recombinant tissue plasminogen activator.静脉重组组织型纤溶酶原激活剂治疗后出血性和缺血性损伤导致早期神经功能恶化的预测因素差异。
J Thromb Thrombolysis. 2020 May;49(4):545-550. doi: 10.1007/s11239-019-02015-4.
7
The Risk of Symptomatic Intracranial Hemorrhage after Thrombolysis for Acute Stroke: Current Concepts and Perspectives.急性卒中溶栓治疗后症状性颅内出血的风险:当前概念与观点
Ann Indian Acad Neurol. 2019 Jul-Sep;22(3):336-340. doi: 10.4103/aian.AIAN_323_18.